---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-22-000164"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2022-02-04T23:59:59+00:00"
generated_at: "2026-06-27T10:58:58.487919+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anavex clarifies AVATAR Phase 3 trial endpoints; plans FDA meeting for Rett syndrome approval

## Summary
- Anavex clarifies that the January 2022 clinicaltrials.gov update was not real-time and does not reflect late endpoint/phase changes.
- AVATAR Phase 3 endpoints were updated per ICH guidelines and approved by UK MHRA and Australian HREC before the study.
- Based on AVATAR Phase 3 and prior Phase 2 success, Anavex plans to meet with FDA to discuss approval pathway for blarcamesine in Rett.
- No FDA-approved drugs for Rett syndrome; blarcamesine has Fast Track, Rare Pediatric Disease, and Orphan Drug designations.

## SEC filing metadata
- accession: 0001731122-22-000164
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2022-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112222000164/0001731122-22-000164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112222000164/e3471_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-22-000164
- JSON: https://secwatch.observer/filing/0001731122-22-000164.json
- Plain text: https://secwatch.observer/filing/0001731122-22-000164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.